Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.

The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

A new lipid nanoparticle system can deliver messenger RNA (mRNA) to the brain via intravenous injection. | Drug Discovery And Development

Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.